Severe renal failure following high-dose ifosfamide and mesna
- 1 May 1989
- journal article
- conference paper
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 23 (5) , 329-330
- https://doi.org/10.1007/bf00292414
Abstract
A 62-year-old woman developed subacute renal failure after the repeated administration of ifosfamide (IFX), despite its combination with continuous sodium 2-mercaptoethane sulfonate (mesna) infusion. Biopsy findings, the possible underlying mechanism, and the existing literature are discussed.This publication has 11 references indexed in Scilit:
- Mesna—a short reviewCancer Treatment Reviews, 1987
- POTENTIATION OF IFOSFAMIDE NEUROTOXICITY, HEMATOTOXICITY, AND TUBULAR NEPHROTOXICITY BY PRIOR CIS-DIAMMINEDICHLOROPLATINUM(II) THERAPY1987
- VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancerCancer Chemotherapy and Pharmacology, 1986
- Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicityEuropean Journal of Cancer and Clinical Oncology, 1984
- High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcomaCancer Chemotherapy and Pharmacology, 1983
- High-dose ifosfamide and mesna as continuous infusion over five days—a phase I/II trialCancer Treatment Reviews, 1983
- Clinical overview of mesnaCancer Treatment Reviews, 1983
- Ifosfamide—Current aspects and perspectivesCancer Treatment Reviews, 1983
- Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna)European Journal of Cancer and Clinical Oncology, 1982
- Unexpected toxicity in patients treated with iphosphamide.1972